Harbin Pharmaceutical Group Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 11,493.85 million compared to CNY 9,990.56 million a year ago. Net income was CNY 290.5 million compared to CNY 156.42 million a year ago.

Basic earnings per share from continuing operations was CNY 0.12 compared to CNY 0.06 a year ago. Diluted earnings per share from continuing operations was CNY 0.12 compared to CNY 0.06 a year ago.